AARS1: The Alanine tRNA Ligase 1 that Keeps Genes Functional (G16)

Target Name: AARS1

NCBI ID: G16

AARS1

AARS1: The Alanine tRNA Ligase 1 that Keeps Genes Functional

Introduction

The tRNA is a crucial molecule in the process of translation of genetic information from DNA to protein. It brings amino acids to the ribosome, where they are translated into proteins. Genes are made of DNA, and the information in these genes is translated into proteins that perform various functions in the cell. However, the process of translation can be error-prone, and errors can lead to the production of incorrect proteins or even proteins that are harmful to the cell. Alanine tRNA Ligase 1 (AARS1), which plays a critical role in ensuring the accuracy of gene expression.

AARS1: The Name and Function

AARS1 is a protein that is expressed in most tissues of the body. It is a 21 kDa protein that is localized to the cytoplasm of the cell. AARS1 functions as an enzyme that activates the tRNA by recognizing and binding to specific sequences within the tRNA molecule . This activation occurs through a process called Michaelis-Menten kinetics, which are a model that describes the relationship between the rate of a reaction and the concentration of the reactants.

AARS1 has been shown to play a critical role in the regulation of gene expression. It has been shown to interact with various proteins, including those involved in the transcription process. AARS1 has also been shown to play a role in the regulation of protein stability, which is important for maintaining the function of the proteins that are produced by the gene.

Targeting AARS1: A Potential Drug Target

The regulation of gene expression by AARS1 is a potential drug target. By inhibiting the activity of AARS1, drugs can be developed that can treat a variety of diseases, including genetic disorders, neurodegenerative diseases, and cancer.

One of the reasons for targeting AARS1 is its involvement in the regulation of gene expression. By inhibiting the activity of AARS1, drugs can be developed that can treat genetic disorders caused by errors in gene expression. For example, AARS1 has been shown to play a role in the regulation of vesicle transport, which is a critical process in the transport of intracellular vesicles. Mutations in the AARS1 gene have been shown to cause a variety of genetic disorders, including developmental delays, learning disabilities, and mental retardation.

Another reason for targeting AARS1 is its involvement in the regulation of protein stability. By inhibiting the activity of AARS1, drugs can be developed that can treat neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and can be treated by drugs that target the production of beta-amyloid plaques, which are a hallmark of these conditions.

In addition to its involvement in the regulation of gene expression and protein stability, AARS1 has also been shown to play a role in the regulation of cellular signaling pathways. It has been shown to interact with various signaling proteins, including T-cell factor, which is involved in the regulation of immune responses. This interaction between AARS1 and T-cell factor suggests that AARS1 may play a role in the regulation of cellular immune responses.

Conclusion

In conclusion, AARS1 is a protein that is involved in the regulation of gene expression, protein stability, and cellular signaling pathways. It has been shown to play a critical role in the regulation of cellular processes that are essential for the proper functioning of the cell . As a potential drug target, AARS1 is an attractive target for the development of new treatments for a variety of diseases. Further research is needed to fully understand the role of AARS1 in gene expression and to develop effective drugs that can target this protein.

Protein Name: Alanyl-tRNA Synthetase 1

Functions: Catalyzes the attachment of alanine to tRNA(Ala) in a two-step reaction: alanine is first activated by ATP to form Ala-AMP and then transferred to the acceptor end of tRNA(Ala) (PubMed:27622773, PubMed:27911835, PubMed:28493438, PubMed:33909043). Also edits incorrectly charged tRNA(Ala) via its editing domain (PubMed:27622773, PubMed:27911835, PubMed:28493438)

The "AARS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AARS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets